Local RANKL delivery improves socket healing in bisphosphonate treated rats.


Journal

Bone
ISSN: 1873-2763
Titre abrégé: Bone
Pays: United States
ID NLM: 8504048

Informations de publication

Date de publication:
07 2021
Historique:
received: 25 11 2020
revised: 01 04 2021
accepted: 02 04 2021
pubmed: 10 4 2021
medline: 10 7 2021
entrez: 9 4 2021
Statut: ppublish

Résumé

Medication related osteonecrosis of the Jaws (MRONJ) is a severe complication of antiresorptive and anti-angiogenic medications. Osteoclast inhibition is central in MRONJ pathogenesis. Here, we investigated if local application of RANKL (a key molecule in osteoclast activation) could enhance osteoclast generation and improve extraction socket healing in the presence of bisphosphonates. Thirty Wistar-Han rats received one saline or 66 μg/kg zoledronate (ZA) i.p. dose before surgery. A week later, mandibular molars were extracted bilaterally. Collagen tapes infused with water or RANKL were placed in the extraction sockets of 60 hemimandibles of veh (veh/RANKL-, veh/RANKL+) or ZA treated rats (ZA/RANKL-, ZA/RANKL+). Rats were euthanized 3 or 12 days after surgery. Animals euthanized at 12 days received two additional veh or ZA injections. Clinical, radiographic and histologic assessments were performed. Visually, at the 3-day timepoint, no sockets demonstrated complete healing. At the 12-day timepoint, sockets of veh/RANKL- and veh/RANKL+ rats showed intact mucosa, while mucosal defects were noted in ZA/RANKL- rats. Importantly, ZA/RANKL+ sockets showed absence of bone exposure. RANKL delivery increased bone healing in the ZA/RANKL+ sites 12 days after extraction compared to the ZA/RANKL- sites. Histologically, at the 3-day timepoint, ZA/RANKL- sockets demonstrated extensive bone exposure and osteonecrosis. In contrast, ZA/RANKL+ rats showed granulation tissue coverage and significantly reduced osteonecrosis, similar to the veh groups. Importantly, in the ZA/RANKL+ group, osteoclasts attached to the bone surface and osteoclast numbers were higher compared to ZA/RANKL- sites. At the 12-day timepoint, persistent osteonecrosis and bone exposure were detected in the sockets of ZA/RANKL- animals. Contrary, ZA/RANKL+ rats demonstrated socket epithelialization and reduced osteonecrosis. Significantly more total and bony attached osteoclasts persisted in the ZA/RANKL+ vs the ZA/RANKL- group. We present a novel approach towards improving socket healing, in the presence of ZA, by enhancing osteoclastic numbers and attachment through local RANKL application. Our approach is clinically applicable and could improve treatment outcomes of patients on high-dose ZA therapy.

Identifiants

pubmed: 33836308
pii: S8756-3282(21)00107-1
doi: 10.1016/j.bone.2021.115945
pmc: PMC9396533
mid: NIHMS1830298
pii:
doi:

Substances chimiques

Bone Density Conservation Agents 0
Diphosphonates 0
Imidazoles 0
Zoledronic Acid 6XC1PAD3KF

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

115945

Subventions

Organisme : NIDCR NIH HHS
ID : F30 DE028171
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE019465
Pays : United States
Organisme : NIDCR NIH HHS
ID : T32 DE007296
Pays : United States

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Références

J Bone Miner Res. 2019 Jan;34(1):171-181
pubmed: 30184271
J Bone Miner Res. 2015 Jan;30(1):3-23
pubmed: 25414052
Periodontol 2000. 2015 Jun;68(1):122-34
pubmed: 25867983
J Bone Miner Res. 2015 Dec;30(12):2179-87
pubmed: 26018247
J Oral Maxillofac Surg. 2010 May;68(5):959-63
pubmed: 20149510
Clin Exp Metastasis. 2014 Feb;31(2):233-45
pubmed: 24272640
J Natl Cancer Inst. 2004 Jun 2;96(11):879-82
pubmed: 15173273
Bone. 2011 Apr 1;48(4):677-92
pubmed: 21145999
Arch Intern Med. 2004 Jul 26;164(14):1525-30
pubmed: 15277283
Bone. 2019 Jun;123:234-245
pubmed: 30953717
J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56
pubmed: 25234529
J Oral Maxillofac Surg. 2004 May;62(5):527-34
pubmed: 15122554
Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):497-508
pubmed: 26277349
Mol Med Rep. 2015 May;11(5):3212-8
pubmed: 25572286
Bonekey Rep. 2014 Apr 09;3:519
pubmed: 24795813
J Clin Oncol. 2005 May 20;23(15):3314-21
pubmed: 15738536
Osteoporos Int. 2018 Oct;29(10):2315-2321
pubmed: 29967931
J Dent. 1997 May-Jul;25(3-4):233-7
pubmed: 9175351
Clin Interv Aging. 2008;3(3):445-51
pubmed: 18982915
J Oral Maxillofac Surg. 2014 Dec;72(12):2461-8
pubmed: 25262401
J Dent Res. 2013 Oct;92(10):860-7
pubmed: 23906603
PLoS One. 2015 Apr 16;10(4):e0120756
pubmed: 25880208
J Am Osteopath Assoc. 2013 Feb;113(2 Suppl 1):S5-24; quiz S25
pubmed: 23425935
J Oral Maxillofac Surg. 2014 Apr;72(4):702-16
pubmed: 24397946
Nat Rev Mater. 2016 Dec;1(12):
pubmed: 29657852
Osteoporos Int. 2008 Nov;19(11):1613-20
pubmed: 18483689
J Dent Res. 1991 Jan;70(1):50-4
pubmed: 1991860
Osteoporos Int. 2014 Mar;25(3):1141-50
pubmed: 24301537
Int Dent J. 2011 Feb;61(1):19-24
pubmed: 21382029
Bone. 2016 Sep;90:133-41
pubmed: 27327410
Support Care Cancer. 2019 Feb;27(2):383-394
pubmed: 30353228
Trends Mol Med. 2006 Jan;12(1):17-25
pubmed: 16356770
Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):489-96
pubmed: 26412796
J Bone Miner Res. 2016 Aug;31(8):1485-7
pubmed: 27335158
Osteoporos Int. 2013 Aug;24(8):2365-9
pubmed: 23371327
J Bone Miner Res. 2011 Aug;26(8):1871-82
pubmed: 21351151
Intern Med J. 2009 May;39(5):304-16
pubmed: 19220531
Biomed Res Int. 2014;2014:747584
pubmed: 24772435
J Dent Res. 2018 Mar;97(3):312-320
pubmed: 28954199
Eur Urol. 2008 Nov;54(5):1066-72
pubmed: 18602738
Am J Pathol. 2018 Oct;188(10):2318-2327
pubmed: 30059656
J Bone Miner Res. 2015 Sep;30(9):1627-40
pubmed: 25727550
Clin Cancer Res. 2013 Dec 15;19(24):6863-72
pubmed: 24166910
Am J Med. 2013 Jan;126(1):13-20
pubmed: 23177553
Bone. 2010 Jun;46(6):1613-9
pubmed: 20215062
Eur J Rheumatol. 2017 Mar;4(1):46-56
pubmed: 28293453
J Bone Miner Res. 2013 Jul;28(7):1631-40
pubmed: 23426919
J Dent Res. 2010 Mar;89(3):219-29
pubmed: 20139336
Ann N Y Acad Sci. 2012 Aug;1263:29-40
pubmed: 22831177
Curr Opin Pharmacol. 2015 Jun;22:41-50
pubmed: 25854704
Odontology. 2011 Jan;99(1):8-17
pubmed: 21271320
J Oral Maxillofac Surg. 2007 Mar;65(3):573-80
pubmed: 17307613
Bone. 2014 Nov;68:11-9
pubmed: 25093262
Arch Biochem Biophys. 2008 May 15;473(2):139-46
pubmed: 18395508
Ther Adv Musculoskelet Dis. 2013 Jun;5(3):107-11
pubmed: 23858334
J Bone Miner Res. 2014 Nov;29(11):2520-6
pubmed: 24771492
J Bone Miner Res. 2016 Dec 29;32(3):424-430
pubmed: 28099754
J Nucl Med. 1978 Jul;19(7):845-7
pubmed: 660289
J Bone Miner Res. 2009 Feb;24(2):182-95
pubmed: 19016581
J Oral Maxillofac Res. 2019 Sep 05;10(3):e2
pubmed: 31620264

Auteurs

Akrivoula Soundia (A)

Division of Diagnostic and Surgical Sciences, UCLA School of Dentistry, Los Angeles, CA, USA.

Danny Hadaya (D)

Division of Diagnostic and Surgical Sciences, UCLA School of Dentistry, Los Angeles, CA, USA.

Yee Chau (Y)

Division of Diagnostic and Surgical Sciences, UCLA School of Dentistry, Los Angeles, CA, USA.

Ioannis Gkouveris (I)

Department of Oral and Maxillofacial Pathology and Medicine, School of Dentistry, National and Kapodistrian University of Athens, Greece.

Olga Bezouglaia (O)

Division of Diagnostic and Surgical Sciences, UCLA School of Dentistry, Los Angeles, CA, USA.

Sarah Dry (S)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Flavia Pirih (F)

Division of Constitutive and Regenerative Sciences, UCLA School of Dentistry, Los Angeles, CA, USA.

Tara Aghaloo (T)

Division of Diagnostic and Surgical Sciences, UCLA School of Dentistry, Los Angeles, CA, USA. Electronic address: taghaloo@dentsitry.ucla.edu.

Sotirios Tetradis (S)

Division of Diagnostic and Surgical Sciences, UCLA School of Dentistry, Los Angeles, CA, USA. Electronic address: stetradis@dentistry.ucla.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH